Evidence map›Paper›PMID 40768012›Full record

ArticleInternational journal of clinical oncology2025

Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases.

Carey Anders, Edward Neuberger, Naomi R M Schwartz, Karen Bartley, Shu Wang, Yutong Liu, Brian T Pittner, Peter A Kaufman, Jane Meisel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carey AndersDuke Cancer Institute (Breast Clinic), Durham, NC, USA. carey.anders@duke.edu.
Edward NeubergerPfizer Inc, South San Francisco, CA, USA.
Naomi R M SchwartzPfizer Inc, South San Francisco, CA, USA.
Karen BartleyPfizer Inc, South San Francisco, CA, USA.
Shu WangGenesis Research, Hoboken, NJ, USA.
Yutong LiuGenesis Research, Hoboken, NJ, USA.
Brian T PittnerPfizer Inc, South San Francisco, CA, USA.
Peter A KaufmanMedical Center (Hematology and Oncology), University of Vermont, Burlington, VT, USA.
Jane MeiselWinship Cancer Institute, Atlanta, GA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe real-world characteristics and clinical outcomes among patients with HER2+ MBC receiving tucatinib-based treatments.

methodsThis retrospective study included patients diagnosed with HER2+ MBC between January 2017 and December 2022 from two administrative health claims databases, Merative

resultsThere were 150 patients in MarketScan

conclusionThese results reinforce the real-world effectiveness of tucatinib in patients with HER2+ MBC, including patients with prior T-DXd treatment. Further research is needed to determine the optimal treatment sequencing for patients with HER2+ MBC.

Indexed as

Brain NeoplasmsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesPyridinesQuinazolinesAdultAgedAntineoplastic Combined Chemotherapy ProtocolsDatabases, FactualFemaleHumansMiddle AgedOxazolesRetrospective StudiesTreatment OutcomeERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesOxazolesPyridinesQuinazolinestucatinibHER2+Metastatic breast cancerReal-worldTrastuzumab deruxtecanTucatinib

Identifiers

PMID40768012
PMCPMC12474727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.